Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Jahr

2022

Autoren

Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T.

Verlag

Mult Scler. 2022 Apr;28(5):842-846.

Link

https://doi.org/10.1177/13524585211061335

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland

Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

Consensus quality indicators for monitoring multiple sclerosis

Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany

Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis